MODEL VERDICT
Immunic, Inc. (IMUX)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 2.56 | 2.35 | 0.39 | 5.44 | 1.65 |
| P/B Ratio | 2.12 | 1.64 | 0.39 | 5.44 | 1.74 |
Insufficient data to determine relative valuation for IMUX.
Fair value could not be computed for IMUX due to insufficient comparable data.
IMUX's current P/E of -1.4x compares to the industry median of 22.6x (6 peers in the group). This represents a -106.3% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
12 analysts cover IMUX with a consensus rating of Buy. The consensus price target is $2.50 (range: $2.50 — $2.50), implying +184.1% upside from the current price. Grade breakdown: Strong Buy (0), Buy (10), Hold (2), Sell (0), Strong Sell (0).
The model confidence score is 49/100, based on: data completeness (0), peer quality (25), historical depth (16), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for IMUX.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.